The U.S. Food and Drug Administration has approved Johnson & Johnson’s Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease.
The U.S. Food and Drug Administration has approved Johnson & Johnson’s Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease.
Leave A Comment